This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Janssen Scientific Affairs, LLC
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01598051
First received: April 20, 2012
Last updated: March 9, 2017
Last verified: March 2017
  Purpose

The objective of this study is to understand if Rivaroxaban can improve treatment satisfaction of Warfarin patients and assess the safety and effectiveness of Xarelto in real clinical practice.

A total of 725 patients are to be enrolled and followed for a 6 months.period. QOL survey will be conducted at month 0, 3, 6 using ACTS/TSQM.

This study is categorized as a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Xarelto for SPAF.


Condition Intervention
Brain Ischemia Drug: Rivaroxaban (Xarelto_ BAY59-7939)

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Treatment Satisfaction Under Rivaroxaban (ACTS/TSQM)

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Improvement of treatment satisfaction (Evaluated through ACTS and TSQM questionnaires) [ Time Frame: Up to 6 months ]
  • Incidence of ADRs and serious AEs (especially for hemorrhagic events, and liver disfunction with increase of liver-function-relating enzymes including bilirubin) [ Time Frame: Up to 6 months ]
  • Incidence of events of stroke [ Time Frame: Up to 6 months ]
  • Incidence of events of non-central nervous system embolism [ Time Frame: Up to 6 months ]

Secondary Outcome Measures:
  • Determination of patient's demography which might affect the QOL, safety and efficacy of Xarelto using ACTS and TSQM questionnaires [ Time Frame: Baseline ]
  • Determination of patient's medical history which might affect the QOL, safety and efficacy of Xarelto using ACTS and TSQM questionnaires [ Time Frame: Baseline ]
  • Determination of patient's background which might affect the QOL, safety and efficacy of Xarelto using ACTS and TSQM questionnaires [ Time Frame: Baseline ]

Enrollment: 741
Actual Study Start Date: May 31, 2012
Estimated Study Completion Date: January 17, 2020
Primary Completion Date: June 9, 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1
Patients treated with Xarelto under practical manner for SPAF.
Drug: Rivaroxaban (Xarelto_ BAY59-7939)
Patients treated with Xarelto under practical manner for SPAF.

  Eligibility

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with non-valvular atrial fibrillation necessary for the treatment for prevention of ischemic stroke and systemic embolism
Criteria

Inclusion Criteria:

  • Patients treated by Warfarin for their atrial fibrillation for at least two months at the time of the study initiation.
  • Rivaroxaban naïve patients
  • Patients 20 years old or older.
  • Patients who agree to sign the inform consent

Exclusion Criteria:

  • Patients who are contraindicated by product label
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01598051

Locations
Japan
Many Locations, Japan
Sponsors and Collaborators
Bayer
Janssen Scientific Affairs, LLC
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01598051     History of Changes
Other Study ID Numbers: 16296
Study First Received: April 20, 2012
Last Updated: March 9, 2017

Keywords provided by Bayer:
Xarelto
SPAF
QOL

Additional relevant MeSH terms:
Ischemia
Brain Ischemia
Pathologic Processes
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Rivaroxaban
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants

ClinicalTrials.gov processed this record on August 17, 2017